APA (7th ed.) Citation

Contieri, R., Mollica, V., Shariat, S., & Pradere, B. (2026). Comment on: ALBAN (GETUG-AFU 37): a phase III, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC). Annals of Oncology, 37(5), 747. https://doi.org/10.1016/j.annonc.2026.01.003

Chicago Style (17th ed.) Citation

Contieri, R., V. Mollica, S.F Shariat, and B. Pradere. "Comment on: ALBAN (GETUG-AFU 37): A Phase III, Randomized, Open-label, International Trial of Intravenous Atezolizumab and Intravesical Bacillus Calmette-Guérin (BCG) Versus BCG Alone in BCG-naive High-risk, Non-muscle-invasive Bladder Cancer (NMIBC)." Annals of Oncology 37, no. 5 (2026): 747. https://doi.org/10.1016/j.annonc.2026.01.003.

MLA (9th ed.) Citation

Contieri, R., et al. "Comment on: ALBAN (GETUG-AFU 37): A Phase III, Randomized, Open-label, International Trial of Intravenous Atezolizumab and Intravesical Bacillus Calmette-Guérin (BCG) Versus BCG Alone in BCG-naive High-risk, Non-muscle-invasive Bladder Cancer (NMIBC)." Annals of Oncology, vol. 37, no. 5, 2026, p. 747, https://doi.org/10.1016/j.annonc.2026.01.003.